Evodiamine significantly reduced the growth of prostate cancer xenografts in nude mice in vivo by suppressing the expressions of HIF-1α, lactylation of histone 3 on lysine residue 18 (H3K18la), GPX4, PD-L1, and proliferation markers. The gene discussed is HIF1A; the disease is prostate carcinoma.